MedTrace Logo

A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer

NCT07241767 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-04-08

No results posted yet for this study

Summary

Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.

Conditions

Interventions

DRUG

FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin

FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin

DRUG

FH-006 ; SHR-1316 ; BP102

FH-006 ; SHR-1316 ; BP102

DRUG

FH-006; SHR-1316 ; SHR-8068

FH-006; SHR-1316 ; SHR-8068

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-12
Primary Completion
2027-11-30
Completion
2028-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07241767 on ClinicalTrials.gov